Jazz Pharmaceuticals PLC

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///PE and share price
    Company & Industry Overviews

    Pfizer’s Medivation Acquisition: What You Need to Know

    On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

    By Margaret Patrick
  • uploads///pulse trace _
    Company & Industry Overviews

    Analyst Ratings for Endo International and Peers in August

    In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY decline of 18.4%.

    By Margaret Patrick
  • uploads///LPLA
    Consumer

    Lone Pine Capital buys a new position in LPL Financial Holdings

    Lone Pine initiated a new position in LPL Financial Holdings (LPLA) last quarter that accounts for 1.95% of the fund’s total 1Q portfolio.

    By Samantha Nielson
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02

    Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.

    By Peter Neil
  • uploads///EQIX
    Consumer

    Stephen Mandel’s Lone Pine Capital buys a new position in Equinix

    Lone Pine initiated a new position in Equinix (EQIX) last quarter that accounts for 1.81% of the fund’s total 1Q portfolio. Lone Pine had exited the position in 4Q 2013 and restarted it last quarter.

    By Samantha Nielson
  • uploads///Strensiq
    Earnings Report

    How Alexion Plans to Fuel Strensiq Sales

    With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.

    By Jillian Dabney
  • uploads///Xyrem
    Company & Industry Overviews

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Jazz Pharmaceuticals: Analysts’ View in November

    On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.

    By Daniel Collins
  • uploads///VRX revenue
    Company & Industry Overviews

    A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance

    In 3Q16, Valeant Pharmaceuticals (VRX) generated revenues of $2.4 billion, compared with $2.2 billion in 3Q17.

    By Kenneth Smith
  • uploads///VRX divestments
    Company & Industry Overviews

    Inside Valeant Pharmaceuticals’ Recent Divestments

    Valeant Pharmaceuticals (VRX) was granted the worldwide exclusive licensing rights for manufacturing and selling the EyeGate 2 delivery system.

    By Kenneth Smith
  • uploads///VRX analysts reco
    Company & Industry Overviews

    Valeant Pharmaceuticals on the Street: Analyst Ratings This February

    Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///Jazz analyst
    Company & Industry Overviews

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Alnylam Pharmaceuticals and Peers

    On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

    By Margaret Patrick
  • uploads///Azilect
    Company & Industry Overviews

    How TEVA’s CNS Drugs Performed in 1H17

    In 1H17, Teva Pharmaceutical’s (TEVA) CNS (central nervous system) business generated revenues of ~$2.3 billion, or ~16% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Erwinaze
    Company & Industry Overviews

    Where Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenues of ~$49 million, which represents a ~1% fall YoY and a ~4% fall QoQ.

    By Daniel Collins
  • uploads///Defitelio
    Company & Industry Overviews

    How Is Jazz’s Defitelio Positioned after 2Q17?

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.

    By Daniel Collins
  • uploads///Xyrem
    Company & Industry Overviews

    This Could Drive Jazz Pharmaceuticals’ Revenue Growth

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of ~$298 million, which represents ~6% growth YoY and ~10% growth QoQ.

    By Daniel Collins
  • uploads///Vyxeos
    Company & Industry Overviews

    Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018

    In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17

    In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Acadia Pharmaceuticals in September

    Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Technology Platforms and Research Programs Drive LGND’s Partnerships

    Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals

    Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals’ Shots-on-Goal Business Model

    Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017

    In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Jazz Pharmaceuticals Is Focused on Label Expansion of Defitelio

    Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Jazz Pharmaceuticals Aims to Boost Vyxeos Sales in 2017

    In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Jazz Pharmaceuticals Expects for Vyxeos

    If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    JAZZ Is Focused on Increasing Market Adoption of Defitelio

    Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Defitelio Continues to Demonstrate Robust Demand Trends in 2017

    Jazz Pharmaceuticals expects Defitelio to report revenues in the range of $130 million to $150 million globally in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside the Efficacy of JAZZ’s JZP-110 in Obstructive Sleep Apnea Trials

    This trial demonstrated the efficacy and safety of JAZZ’s JZP-110 in both the MWT and sleep latency tests at all dosages at the end of weeks 4 and 12.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Erwinaze Sales May Remain Flat in 2017

    Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Future of JAZZ’s Low-Sodium Investigational Drugs

    A 9-mg dose of JAZZ’s Xyrem, which contains 1,640 mg of sodium, has caused physicians to be reluctant to prescribe the drug to ~20% of their patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Alone Could Boost Xyrem’s Addressable Market in 2018

    To expand Xyrem’s addressable market, JAZZ has been evaluating the efficacy of Xyrem in pediatric narcolepsy patients with cataplexy and excessive sleepiness.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Xyrem’s Solid Demand Trends in 2017

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Jazz’s Net Profit Margin Expectations for 2017

    For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Jazz Is Expected to Report a Robust Revenue Growth Rate

    On August 3, JAZZ managed to secure regulatory approval from the FDA for its innovative drug, Vyxeos, as a treatment option for two types of acute myeloid leukemia.

    By Margaret Patrick
  • uploads///anr
    Company & Industry Overviews

    What Are Analysts Saying about Horizon Pharma?

    According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”

    By Jillian Dabney
  • uploads///narcolepsy
    Company & Industry Overviews

    Can Xyrem Maintain Leadership in the Narcolepsy Space?

    Jazz Pharmaceuticals’ (JAZZ) Xyrem is a drug for cataplexy and excessive daytime sleepiness occurring in patients with narcolepsy, a serious orphan disease.

    By Jillian Dabney
  • uploads///VOD
    Company & Industry Overviews

    Defitelio: Volume and Pricing Challenges

    Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).

    By Jillian Dabney
  • uploads///DLTR
    Consumer

    Stephen Mandel’s Lone Pine Capital sells its shares in Dollar Tree

    Lone Pine shed a position in Dollar Tree Inc. (DLTR) last quarter that accounted for 1.97% of the fund’s 4Q 2013 portfolio.

    By Samantha Nielson
  • uploads///ADBE
    Consumer

    Mandel’s Lone Pine Capital starts a new position in Adobe Systems

    Lone Pine initiated a new position in Adobe Systems Inc. (ADBE) last quarter that accounts for 1.89% of the fund’s total 1Q portfolio.

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.